Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 18 tags : Europe save search
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at 7th Congress of the European Academy of Neurology
Published: 2021-06-18 (Crawled : 19:00) - globenewswire.com
TGTX | $13.99 -1.83% -1.86% 2.7M
|
Health Technology
| Email alert
Add to watchlist
presentation multiple sclerosis europe sclerosis phase 3 trial
Bristol Myers Squibb Receives European Commission Approval for Onureg® (azacitidine tablets) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia
Published: 2021-06-18 (Crawled : 18:00) - biospace.com/
BMY | $48.86 -0.27% 0.0% 16M
|
Health Technology
|
| O: -0.55%
H: 0.5%
C: 0.11%
myeloid leukemia europe therapy leukemia approval acute myeloid leukemia
Global Meat Substitutes Market 2021: Europe Dominates with 40% Market Share - Forecast to 2029
Published: 2021-06-18 (Crawled : 17:00) - prnewswire.com
K S | $58.75 1.05% 0.0% 2.3M
|
Consumer Non-Durables
|
| O: -0.36%
H: 0.0%
C: -1.1%
europe market
Horizon Therapeutics plc Announces Multiple Presentations on Neuromyelitis Optica Spectrum Disorder (NMOSD) at the 7th Congress of the European Academy of Neurology (EAN)
Published: 2021-06-18 (Crawled : 17:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.84%
H: 4.24%
C: 3.55%
presentation europe
Europe Solar Panel Recycling Market 2020-2027: Trend Outlook and Growth Opportunities
Published: 2021-06-18 (Crawled : 16:00) - prnewswire.com
SPWR | $1.94 -1.02% -1.03% 5M
|
Producer Manufacturing
|
| O: -2.91%
H: 3.7%
C: -2.2%
CSIQ | News | $14.95 0.54% 0.47% 1.3M
|
Producer Manufacturing
|
| O: -0.79%
H: 2.22%
C: 0.69%
solar europe growth
European Commission approves Aubagio® (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis
Published: 2021-06-18 (Crawled : 14:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.9%
H: 1.38%
C: 1.21%
multiple sclerosis treatment europe therapy children sclerosis
Scholar Rock to Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic (PK) and Pharmacodynamic (PD) Data at the 2021 European Academy of Neurology Congress
Published: 2021-06-18 (Crawled : 13:00) - biospace.com/
SRRK 4 | $14.11 -4.6% -4.82% 430K
|
Health Technology
|
| O: -1.72%
H: 3.46%
C: 2.28%
phase 2 europe results trial trial results
Gainers vs Losers
| 65% | 35% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 210M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.